KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Receivables: 2020-2024

Historic Receivables for Esperion Therapeutics (ESPR) over the last 5 years, with Dec 2024 value amounting to $80.1 million.

  • Esperion Therapeutics' Receivables rose 75.42% to $119.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $388.2 million, marking a year-over-year increase of 67.82%. This contributed to the annual value of $80.1 million for FY2024, which is 65.26% up from last year.
  • Esperion Therapeutics' Receivables amounted to $80.1 million in FY2024, which was up 65.26% from $48.5 million recorded in FY2023.
  • In the past 5 years, Esperion Therapeutics' Receivables registered a high of $80.1 million during FY2024, and its lowest value of $12.4 million during FY2020.
  • In the last 3 years, Esperion Therapeutics' Receivables had a median value of $48.5 million in 2023 and averaged $54.1 million.
  • Data for Esperion Therapeutics' Receivables shows a peak YoY skyrocketed of 85.13% (in 2021) over the last 5 years.
  • Esperion Therapeutics' Receivables (Yearly) stood at $12.4 million in 2020, then surged by 85.13% to $22.9 million in 2021, then spiked by 47.07% to $33.7 million in 2022, then surged by 43.78% to $48.5 million in 2023, then surged by 65.26% to $80.1 million in 2024.